Protocol Ledger

NCT07766018 · Phase II · RECRUITING

A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT07766018 sponsored by Stemline Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-18 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07766018
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07766018
Protocol FieldVerified Registry Value
NCT IdentifierNCT07766018
Consolidated Lead SponsorStemline Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2026-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07766018
Hospital Research SiteLocationSite Profile
Chiba Cancer CenterChiba, JapanOpen Hospital Dossier ->
Kyushu University HospitalFukuoka, JapanOpen Hospital Dossier ->
Hiroshima University HospitalHiroshima, JapanOpen Hospital Dossier ->
Kumamoto University HospitalKumamoto, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI